Positron Emission Tomography (PET) Imaging of Participants With Confirmed Prostate Cancer Using 64Cu-SAR-bisPSMA (PROPELLER)

Clarity Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Prostatic Neoplasms

Treatments: Drug: 64Cu-SAR-bisPSMA

Study type: Interventional

Funder types: Industry

Identifiers

NCT04839367

CLP03

Details and patient eligibility

About

The aim of this study is to determine the safety and tolerability of 64Cu-SARbisPSMA in participants with untreated, confirmed Prostate Cancer.

Full description

This is a multi-centre, blinded review, dose ranging, non-randomized study of 64Cu-SAR-bisPSMA administered to participants with confirmed Prostate Cancer. 30 eligible participants will be allocated (1:1:3) to 1 of 3 dosing cohorts to be administered with 64Cu-SAR-bisPSMA 100 MBq, 150 MBq or 200 MBq. PET/CT scan images will be sent to blinded central readers to assess the capacity of 64Cu-SAR-bisPSMA to detect primary Prostate Cancer, to assess image quality of the various dose cohorts, and to assess the PET/CT scan features of 64Cu-SAR-bisPSMA in comparison standard of care.

Enrollment: 30 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent;

• ≥18 years of age;

• Life expectancy >3 months;

• Confirmation of Prostate Cancer by histopathology and planned radical prostatectomy;

• Have ≥1 of the following intermediate- to high-risk features:

  1. PSA level greater than or equal to 10.0 ng/ml within 12 weeks prior to enrolment;
  2. International Society of Urological Pathology (ISUP) Grade Group 3 (i.e. Gleason score of 7 (4+3) or above;
  3. Clinical stage greater than or equal to T2b;

• Participants must have adequate renal function;

• Sexually active participants who have female partners of childbearing potential: Partner and/or participant must agree to use an acceptable form of contraception. Further participants must refrain from donating sperm;

• A 68Ga-PSMA-11 PET/CT scan performed within 5 weeks, but not closer than 6 hours prior to the administration of 64Cu-SAR-bisPSMA.

Exclusion criteria

• Prior prostatectomy or any other treatment for Prostate Cancer, including Androgen Deprivation Therapy and radiation therapy;
• Previous treatment with PSMA-targeted therapy within 3 months prior to enrolment, and administration of other investigational agents within 4 weeks prior to entering the study (except 68Ga-PSMA-11);
• Known hypersensitivity to the components of 64Cu-SAR-bisPSMA;
• Diagnosed with other malignancies that are expected to alter life expectancy or may interfere with disease assessment. However, participants with a prior history of malignancy that has been adequately treated and who have been disease free for more than 3 years are eligible, as are participants with adequately treated non-melanoma skin cancer, superficial bladder cancer;
• Any serious medical condition which the Investigator feels may interfere with the procedures or evaluations of the study;
• Patients unwilling or unable to comply with protocol or with a history of noncompliance or inability to grant informed consent.

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Sequential Assignment

Masking: None (Open label)

---

30 participants in 3 patient groups

Cohort 1 - 100 MBq 64Cu-SAR-bisPSMA

Experimental group

Description:

Participants will receive a single administration, a bolus injection of 100 MBq 64Cu-SAR-bisPSMA.

Treatment:

Drug: 64Cu-SAR-bisPSMA

Cohort 2 - 150 MBq 64Cu-SAR-bisPSMA

Experimental group

Description:

Participants will receive a single administration, a bolus injection of 150 MBq 64Cu-SAR-bisPSMA.

Treatment:

Drug: 64Cu-SAR-bisPSMA

Cohort 3 - 200 MBq 64Cu-SAR-bisPSMA

Experimental group

Description:

Participants will receive a single administration, a bolus injection of 200 MBq 64Cu-SAR-bisPSMA.

Treatment:

Drug: 64Cu-SAR-bisPSMA